Alpha Tau Medical is a clinical-stage oncology company developing Alpha DaRT, a proprietary technology that harnesses alpha particles for targeted radiation therapy of solid tumors. The technology embeds Radium-224 in radioactive sources that are injected directly into tumors, where radioactive daughter atoms diffuse and deliver localized alpha radiation with minimal damage to surrounding healthy tissue, offering potential advantages over conventional external beam radiotherapy. The company is advancing multiple clinical trials across several cancer types including head and neck squamous cell carcinoma, glioblastoma, and pancreatic cancer, with regulatory approvals already granted in Israel and Japan; it plans to commercialize primarily through direct distribution in core markets such as the United States and Europe, supported by manufacturing facilities and distribution partnerships.